MyFinsight
Home
Blog
About
Maturities of short-term
investments
$112,500K
(-67.16%↓ Y/Y)
Proceeds from issuance of
stock under equity...
$1,499K
(127.81%↑ Y/Y)
Net cash provided by
(used in) investing...
$92,209K
(317.13%↑ Y/Y)
Net cash provided by
financing activities
$1,499K
(127.81%↑ Y/Y)
Canceled cashflow
$20,291K
Net decrease in cash
and cash...
$31,159K
(121.86%↑ Y/Y)
Canceled cashflow
$62,549K
Purchases of short-term
investments
$19,635K
(-94.88%↓ Y/Y)
Purchases of property and
equipment
$656K
(-62.51%↓ Y/Y)
Accrued expenses and
other current...
$9,659K
Share-based compensation
expense
$8,209K
(-44.50%↓ Y/Y)
Prepaid expenses and
other current assets
-$4,339K
(-150.74%↓ Y/Y)
Depreciation expense
$369K
(-20.65%↓ Y/Y)
Operating lease
right-of-use and other...
-$336K
(-111.50%↓ Y/Y)
Operating lease
liabilities
$141K
Non-cash interest
expense
$111K
(-59.04%↓ Y/Y)
Other long-term
liabilities
$109K
(-82.64%↓ Y/Y)
Net cash used in
operating activities
-$62,549K
(37.89%↑ Y/Y)
Canceled cashflow
$23,273K
Net loss
-$68,327K
(44.70%↑ Y/Y)
Contract liabilities
-$10,364K
(-143.61%↓ Y/Y)
Accounts payable
-$4,650K
Inventory
$1,642K
Amortization of premium and
accretion of discounts on...
$741K
(-85.70%↓ Y/Y)
Accounts receivable, net
$98K
Back
Back
Cash Flow
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)
source: myfinsight.com